1. HRMY's management will speak at Goldman Sachs Healthcare Conference on June 9, 2025. 2. The conference may offer insights into HRMY's future therapeutic innovations. 3. Webcast available on Harmony's investor page for updates and strategic announcements.
Participation in high-profile events can boost investor confidence and market visibility, similar to past instances where companies have seen stock price increases after participating in similar conferences.
The engagement at a significant healthcare conference suggests future business potential and draws attention from investors, which could influence trading volume and price.
The event is imminent, likely affecting stock sentiment immediately, as past similar conferences showed quick price shifts post-announcement.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.